+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Beta Lactam & Beta Lactamase Inhibitors Market - Global Forecast 2026-2032- Product Image
Beta Lactam & Beta Lactamase Inhibitors Market - Global Forecast 2026-2032- Product Image
Sale

Beta Lactam & Beta Lactamase Inhibitors Market - Global Forecast 2026-2032

  • Report

  • 192 Pages
  • July 2026
  • Region: Global
  • 360iResearch™
  • ID: 5715533
UP TO OFF until Dec 31st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Beta Lactam & Beta Lactamase Inhibitors Market is projected to reach USD 32.35 Billion in 2026. It is expected to continue growing at a CAGR of 4.64%, reaching USD 42.58 Billion by 2032.

Beta lactam and beta lactamase inhibitor therapies remain central to antibacterial treatment because beta lactam antibiotics, including penicillins, cephalosporins, carbapenems, and monobactams, target bacterial cell wall synthesis with a long-established clinical safety profile. Their continued relevance is being reshaped by antimicrobial resistance, particularly the spread of extended-spectrum beta lactamases, AmpC enzymes, and carbapenemases that reduce the effectiveness of traditional agents. In response, beta lactamase inhibitors are increasingly used to restore or extend antibacterial activity against resistant Gram-negative pathogens in hospital-acquired infections, complicated urinary tract infections, intra-abdominal infections, bloodstream infections, and pneumonia. The sector is closely linked to antimicrobial stewardship, regulatory incentives for priority pathogens, diagnostic innovation, and infection prevention strategies. Clinical demand is strongest where healthcare systems face rising multidrug-resistant infections, expanding intensive care utilization, and heightened surveillance requirements. As resistance mechanisms evolve, decision-makers are prioritizing targeted therapy, rapid susceptibility testing, reliable supply chains, and responsible antibiotic use to preserve efficacy while improving patient outcomes.

Transformative Shifts in the Treatment Landscape

The beta lactam and beta lactamase inhibitors landscape is undergoing a structural shift from broad empiric prescribing toward precision-guided antibacterial therapy. Hospitals are increasingly integrating antimicrobial stewardship programs, rapid microbiology, and local resistance data to guide selection of inhibitor combinations and reduce unnecessary exposure. The emergence of difficult-to-treat resistant Gram-negative organisms has accelerated interest in novel combinations designed to address specific enzyme classes, including serine beta lactamases and selected carbapenemase-producing strains. Regulatory agencies and public health bodies continue to classify antimicrobial resistance as a critical health threat, encouraging evidence-based use, infection surveillance, and development of agents active against priority pathogens. Procurement strategies are also changing as health systems seek dependable access to essential antibiotics while managing shortages and quality requirements. At the same time, clinical guidelines increasingly emphasize de-escalation, dose optimization, renal adjustment, extended or continuous infusion where appropriate, and pharmacokinetic-pharmacodynamic principles, reinforcing a more disciplined model for beta lactamase inhibitor deployment across acute care settings.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence the beta lactam and beta lactamase inhibitors field across discovery, diagnostics, clinical decision support, and supply resilience. In drug discovery, machine learning models are being used to screen chemical libraries, predict beta lactamase binding behavior, prioritize molecular modifications, and identify candidates with improved activity against resistant pathogens. In clinical microbiology, AI-assisted interpretation of susceptibility patterns and genomic resistance markers can support faster therapy selection when validated against laboratory standards. In hospitals, predictive analytics can help identify patients at risk for multidrug-resistant infections, optimize empiric therapy pathways, and strengthen antimicrobial stewardship interventions. AI can also improve pharmacovigilance by detecting safety signals from real-world data and enhance supply chain planning by anticipating demand volatility for critical injectable antibiotics. However, implementation must be evidence-led, clinically governed, and aligned with data privacy, model transparency, antimicrobial stewardship, and laboratory validation requirements to avoid inappropriate prescribing, bias, or overreliance on algorithmic outputs.

Key Regional Insights

Asia-Pacific is a critical region for beta lactam and beta lactamase inhibitors due to high infectious disease burden, dense urban populations, substantial antibiotic consumption, and documented challenges with antimicrobial resistance across several healthcare systems. China, India, Japan, South Korea, Australia, and ASEAN economies are strengthening surveillance, stewardship, and domestic pharmaceutical capabilities, while hospital demand remains closely tied to resistant Gram-negative infections, critical care expansion, and improved laboratory capacity. North America is characterized by advanced hospital stewardship programs, strong regulatory oversight, broad use of susceptibility testing, and sustained public health attention to carbapenem-resistant Enterobacterales, extended-spectrum beta lactamase-producing organisms, and other multidrug-resistant pathogens. Europe benefits from coordinated antimicrobial resistance surveillance, guideline-driven prescribing, pharmacovigilance, and strong emphasis on infection prevention, although resistance patterns vary significantly between northern, western, southern, and eastern countries. Latin America faces a mixed landscape where urban tertiary hospitals manage complex resistant infections while access, diagnostics, and stewardship capacity remain uneven across public and private systems. The Middle East is increasing investment in hospital infrastructure, antimicrobial stewardship, and infection control, with GCC countries emphasizing healthcare modernization, surveillance, and protocol-based management of hospital-acquired infections. Africa faces the dual challenge of high infectious disease burden and constrained diagnostic access, making appropriate beta lactam use, quality-assured supply, antimicrobial stewardship, and resistance monitoring essential for patient care and public health.

Key Group Insights

ASEAN countries are increasingly important in the beta lactam and beta lactamase inhibitors landscape as governments expand universal health coverage, hospital capacity, and antimicrobial resistance action plans while managing high antibiotic utilization and variable laboratory infrastructure. The GCC is advancing healthcare modernization, specialist hospital networks, infection control programs, and antimicrobial stewardship frameworks, supporting greater use of protocol-driven therapy for resistant hospital pathogens. The European Union provides one of the most structured environments for antimicrobial resistance surveillance, pharmacovigilance, quality standards, and cross-border public health coordination, making it influential in guideline-based prescribing, evidence generation, and conservation-focused antibiotic policy. BRICS economies combine large patient populations, substantial pharmaceutical manufacturing capabilities, and rising hospital demand, but they also face diverse resistance patterns and uneven stewardship maturity, creating strong need for diagnostics-led antibiotic selection and quality-assured supply. G7 countries are influential through advanced regulatory science, public health surveillance, research funding, stewardship initiatives, and policy attention to priority resistant pathogens and hospital-acquired infections. NATO member states, many of which overlap with advanced healthcare economies, place additional emphasis on medical readiness, secure supply chains, and response capacity for infectious disease threats, reinforcing the strategic importance of reliable beta lactam and beta lactamase inhibitor access.

Key Country Insights

The United States remains a major center for beta lactam and beta lactamase inhibitor utilization due to advanced hospital care, robust stewardship expectations, and surveillance of urgent resistant threats, including carbapenem-resistant and extended-spectrum beta lactamase-producing organisms. Canada emphasizes public health surveillance, stewardship, and equitable access across provincial healthcare systems, while Mexico faces growing demand in urban hospitals alongside challenges in resistance monitoring and appropriate antibiotic use. Brazil has significant hospital-based need driven by resistant Gram-negative infections and large public and private healthcare networks. In Europe, the United Kingdom, Germany, France, Italy, and Spain rely on guideline-led prescribing, microbiology capacity, and stewardship programs, though southern European countries have historically reported higher resistance pressures for several Gram-negative pathogens than some northern counterparts. Russia presents a complex environment shaped by hospital infection burden, regional variation in antimicrobial resistance, and evolving stewardship priorities. China and India are pivotal due to large populations, high antibiotic consumption, domestic manufacturing capabilities, and intensified national action plans for antimicrobial resistance. Japan and South Korea combine advanced diagnostics, aging populations, and strong hospital systems, supporting structured use of newer combinations where clinically indicated. Australia has well-developed stewardship and surveillance systems, with prescribing shaped by national guidance, local resistance patterns, and infection control standards.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence-based portfolio strategies that address clinically significant resistance mechanisms rather than undifferentiated antibiotic expansion. Investment in beta lactamase inhibitor innovation should be paired with validated companion diagnostics, rapid susceptibility testing partnerships, and pharmacokinetic-pharmacodynamic optimization to support precise clinical use. Manufacturers and healthcare stakeholders should strengthen quality-assured production, diversified sourcing, and shortage mitigation plans for essential beta lactam injectables and oral formulations. Engagement with antimicrobial stewardship programs is essential, including education on appropriate indications, de-escalation, renal dose adjustment, infusion strategies, therapeutic drug monitoring where available, and resistance monitoring. Organizations should generate real-world evidence on clinical outcomes, safety, resistance emergence, and health system value without encouraging unnecessary prescribing. Access strategies should reflect the public health value of novel antibiotics while supporting conservation through controlled use models. Leaders should also collaborate with hospitals, laboratories, regulators, and public health agencies to improve surveillance data, stewardship compliance, and access to effective therapy in regions with high resistance burden and limited diagnostic capacity.

Research Methodology

This executive summary is developed through secondary research, clinical and regulatory source review, and structured interpretation of publicly available evidence on beta lactam antibiotics, beta lactamase inhibitors, antimicrobial resistance, stewardship practices, regional healthcare dynamics, and infectious disease management. The methodology emphasizes verified data from peer-reviewed literature, public health agencies, regulatory communications, antimicrobial resistance surveillance systems, clinical guidelines, essential medicines guidance, and hospital stewardship frameworks. Insights are synthesized by evaluating resistance mechanisms, therapeutic applications, diagnostic adoption, policy developments, supply considerations, and regional healthcare infrastructure. The analysis excludes market sizing, market share, company-specific positioning, and forecasting. Regional, group, and country perspectives are assessed based on documented healthcare capacity, resistance surveillance, stewardship maturity, antibiotic access, and policy direction. Findings are validated through cross-referencing multiple credible sources and aligning terminology with established infectious disease, microbiology, and pharmacology standards to ensure accuracy, relevance, and alignment for industry-specific audiences.

Conclusion

Beta lactam and beta lactamase inhibitor therapies will remain essential to modern infectious disease management, but their long-term value depends on responsible use, resistance-informed prescribing, diagnostic precision, and reliable access. The sector is increasingly shaped by the need to counter multidrug-resistant Gram-negative pathogens while preserving antibiotic effectiveness through stewardship and infection prevention. Artificial intelligence, rapid diagnostics, and real-world evidence can improve discovery, clinical decision-making, pharmacovigilance, and supply planning when implemented with strong validation and governance. Regional differences in resistance burden, healthcare infrastructure, diagnostic access, and stewardship maturity will continue to influence adoption and therapeutic priorities. Industry leaders that align innovation with public health needs, quality manufacturing, surveillance collaboration, and clinically disciplined access models will be best positioned to support sustainable antibacterial care. The most effective strategies will balance therapeutic advancement with conservation, ensuring that beta lactam and beta lactamase inhibitor combinations remain dependable tools against serious bacterial infections.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Beta Lactam & Beta Lactamase Inhibitors Market, by Drug Class
7.1. Introduction
7.2. Carbapenems
7.2.1. Doripenem
7.2.2. Ertapenem
7.2.3. Imipenem
7.2.4. Meropenem
7.3. Cephalosporins
7.3.1. Fifth-Generation Cephalosporins
7.3.2. First-Generation Cephalosporins
7.3.3. Fourth-Generation Cephalosporins
7.3.4. Second-Generation Cephalosporins
7.3.5. Third-Generation Cephalosporins
7.4. Monobactam
7.5. Penicillins
7.5.1. Aminopenicillins
7.5.2. Extended-Spectrum Penicillins
7.5.3. Natural Penicillins
8. Beta Lactam & Beta Lactamase Inhibitors Market, by Route of Administration
8.1. Introduction
8.2. Oral Administration
8.2.1. Capsules
8.2.2. Tablets
8.3. Parenteral Administration
8.3.1. Intramuscular
8.3.2. Intravenous
9. Beta Lactam & Beta Lactamase Inhibitors Market, by Patient Type
9.1. Introduction
9.2. Adult Patients
9.2.1. Middle-Aged Adults
9.2.2. Senior Adults
9.2.3. Young Adults
9.3. Pediatric Patients
9.3.1. Adolescents
9.3.2. Children
9.3.3. Infants
9.3.4. Neonates
10. Beta Lactam & Beta Lactamase Inhibitors Market, by Application
10.1. Introduction
10.2. Gynecological Infections
10.3. Intrabdominal Infections
10.4. Intraoperative Prophylaxis
10.5. Respiratory Infections
10.6. Skin Infections
10.6.1. Cellulitis
10.6.2. Erysipelas
10.6.3. Impetigo
10.7. Urinary Tract Infections
10.7.1. Acute UTI
10.7.2. Chronic UTI
11. Beta Lactam & Beta Lactamase Inhibitors Market, by End User
11.1. Introduction
11.2. Academic Institutions
11.3. Clinics
11.4. Hospitals
11.5. Research Laboratories
12. Beta Lactam & Beta Lactamase Inhibitors Market, by Region
12.1. Asia-Pacific
12.2. North America
12.3. Latin America
12.4. Europe
12.5. Middle East
12.6. Africa
13. Beta Lactam & Beta Lactamase Inhibitors Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Beta Lactam & Beta Lactamase Inhibitors Market, by Country
14.1. United States
14.2. Germany
14.3. China
14.4. United Kingdom
14.5. India
14.6. Japan
14.7. France
14.8. Brazil
14.9. Canada
14.10. Italy
14.11. Mexico
14.12. Russia
14.13. Spain
14.14. Australia
14.15. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. AbbVie Inc.
16.2. Aurobindo Pharma Limited
16.3. Bio-Rad Laboratories, Inc.
16.4. Bristol-Myers Squibb Company
16.5. Centrient Pharmaceuticals Netherlands B.V.
16.6. Cipla Ltd.
16.7. Creative Diagnostics
16.8. F. Hoffmann-La Roche AG
16.9. Marubeni Corporation
16.10. Melinta Therapeutics, LLC
16.11. Merck KGaA
16.12. Novartis AG
16.13. Pfizer Inc.
16.14. Protech Telelinks
16.15. Qpex Biopharma, Inc. by Shionogi Inc.
16.16. SciClone Pharmaceuticals (Holdings) Limited
16.17. Sumitomo Pharma Co., Ltd.
16.18. Thermo Fisher Scientific Inc.
16.19. TOKU-E
16.20. Venatorx Pharmaceuticals, Inc.
16.21. Zai Lab Limited
List of Figures
FIGURE 1. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 7. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL CARBAPENEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL CARBAPENEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL CARBAPENEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL DORIPENEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL DORIPENEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL DORIPENEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL ERTAPENEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL ERTAPENEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL ERTAPENEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL IMIPENEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL IMIPENEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL IMIPENEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL MEROPENEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL MEROPENEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL MEROPENEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL CEPHALOSPORINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL CEPHALOSPORINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL CEPHALOSPORINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL FIFTH-GENERATION CEPHALOSPORINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL FIFTH-GENERATION CEPHALOSPORINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL FIFTH-GENERATION CEPHALOSPORINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL FIRST-GENERATION CEPHALOSPORINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL FIRST-GENERATION CEPHALOSPORINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL FIRST-GENERATION CEPHALOSPORINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL FOURTH-GENERATION CEPHALOSPORINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL FOURTH-GENERATION CEPHALOSPORINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL FOURTH-GENERATION CEPHALOSPORINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL SECOND-GENERATION CEPHALOSPORINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL SECOND-GENERATION CEPHALOSPORINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL SECOND-GENERATION CEPHALOSPORINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL THIRD-GENERATION CEPHALOSPORINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL THIRD-GENERATION CEPHALOSPORINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL THIRD-GENERATION CEPHALOSPORINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL MONOBACTAM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL MONOBACTAM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL MONOBACTAM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL PENICILLINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL PENICILLINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL PENICILLINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL AMINOPENICILLINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL AMINOPENICILLINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL AMINOPENICILLINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL EXTENDED-SPECTRUM PENICILLINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL EXTENDED-SPECTRUM PENICILLINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL EXTENDED-SPECTRUM PENICILLINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL NATURAL PENICILLINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL NATURAL PENICILLINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL NATURAL PENICILLINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL ORAL ADMINISTRATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL ORAL ADMINISTRATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL ORAL ADMINISTRATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL PARENTERAL ADMINISTRATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL PARENTERAL ADMINISTRATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL PARENTERAL ADMINISTRATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL ADULT PATIENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL ADULT PATIENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL ADULT PATIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL MIDDLE-AGED ADULTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL MIDDLE-AGED ADULTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL MIDDLE-AGED ADULTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL SENIOR ADULTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL SENIOR ADULTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL SENIOR ADULTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL YOUNG ADULTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL YOUNG ADULTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL YOUNG ADULTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL PEDIATRIC PATIENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL PEDIATRIC PATIENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL PEDIATRIC PATIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL ADOLESCENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL ADOLESCENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL ADOLESCENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL CHILDREN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL CHILDREN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL CHILDREN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL INFANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL INFANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL INFANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL NEONATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL NEONATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL NEONATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL GYNECOLOGICAL INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL GYNECOLOGICAL INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL GYNECOLOGICAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL INTRABDOMINAL INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL INTRABDOMINAL INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL INTRABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL INTRAOPERATIVE PROPHYLAXIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL INTRAOPERATIVE PROPHYLAXIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL INTRAOPERATIVE PROPHYLAXIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL RESPIRATORY INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL RESPIRATORY INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL RESPIRATORY INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL SKIN INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL SKIN INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL SKIN INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL CELLULITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL CELLULITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL CELLULITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL ERYSIPELAS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL ERYSIPELAS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL ERYSIPELAS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL IMPETIGO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL IMPETIGO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL IMPETIGO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL URINARY TRACT INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL URINARY TRACT INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL URINARY TRACT INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL ACUTE UTI MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL ACUTE UTI MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL ACUTE UTI MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 130. GLOBAL CHRONIC UTI MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL CHRONIC UTI MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 132. GLOBAL CHRONIC UTI MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 133. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 134. GLOBAL ACADEMIC INSTITUTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 135. GLOBAL ACADEMIC INSTITUTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 136. GLOBAL ACADEMIC INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 137. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 138. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 139. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 140. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 141. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 142. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 143. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 144. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 145. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 146. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 147. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 148. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 149. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
TABLE 150. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 151. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
TABLE 152. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 153. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 154. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 155. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 156. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, 2018-2032 (USD MILLION)
TABLE 157. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2032 (USD MILLION)
TABLE 158. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 159. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, 2018-2032 (USD MILLION)
TABLE 160. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
TABLE 161. ASIA-PACIFIC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 162. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 163. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 164. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
TABLE 165. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 166. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
TABLE 167. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 168. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 169. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 170. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 171. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, 2018-2032 (USD MILLION)
TABLE 172. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2032 (USD MILLION)
TABLE 173. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 174. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, 2018-2032 (USD MILLION)
TABLE 175. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
TABLE 176. NORTH AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 177. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 178. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 179. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
TABLE 180. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 181. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
TABLE 182. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 183. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 184. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 185. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 186. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, 2018-2032 (USD MILLION)
TABLE 187. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2032 (USD MILLION)
TABLE 188. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 189. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, 2018-2032 (USD MILLION)
TABLE 190. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
TABLE 191. LATIN AMERICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 192. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 193. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 194. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
TABLE 195. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 196. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
TABLE 197. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 198. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 199. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 200. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 201. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, 2018-2032 (USD MILLION)
TABLE 202. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2032 (USD MILLION)
TABLE 203. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 204. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, 2018-2032 (USD MILLION)
TABLE 205. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
TABLE 206. EUROPE BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 207. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 208. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 209. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
TABLE 210. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 211. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
TABLE 212. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 213. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 214. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 215. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 216. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, 2018-2032 (USD MILLION)
TABLE 217. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2032 (USD MILLION)
TABLE 218. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 219. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, 2018-2032 (USD MILLION)
TABLE 220. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
TABLE 221. MIDDLE EAST BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 222. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 223. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 224. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
TABLE 225. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 226. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
TABLE 227. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 228. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 229. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 230. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 231. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, 2018-2032 (USD MILLION)
TABLE 232. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2032 (USD MILLION)
TABLE 233. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 234. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, 2018-2032 (USD MILLION)
TABLE 235. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
TABLE 236. AFRICA BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 237. GLOBAL BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 238. ASEAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 239. ASEAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 240. ASEAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
TABLE 241. ASEAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 242. ASEAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
TABLE 243. ASEAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 244. ASEAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 245. ASEAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 246. ASEAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 247. ASEAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, 2018-2032 (USD MILLION)
TABLE 248. ASEAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2032 (USD MILLION)
TABLE 249. ASEAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 250. ASEAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, 2018-2032 (USD MILLION)
TABLE 251. ASEAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
TABLE 252. ASEAN BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 253. GCC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 254. GCC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 255. GCC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
TABLE 256. GCC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 257. GCC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
TABLE 258. GCC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 259. GCC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 260. GCC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 261. GCC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 262. GCC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, 2018-2032 (USD MILLION)
TABLE 263. GCC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2032 (USD MILLION)
TABLE 264. GCC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 265. GCC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, 2018-2032 (USD MILLION)
TABLE 266. GCC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
TABLE 267. GCC BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 268. EUROPEAN UNION BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 269. EUROPEAN UNION BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 270. EUROPEAN UNION BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
TABLE 271. EUROPEAN UNION BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 272. EUROPEAN UNION BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
TABLE 273. EUROPEAN UNION BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 274. EUROPEAN UNION BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 275. EUROPEAN UNION BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 276. EUROPEAN UNION BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 277. EUROPEAN UNION BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, 2018-2032 (USD MILLION)
TABLE 278. EUROPEAN UNION BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2032 (USD MILLION)
TABLE 279. EUROPEAN UNION BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 280. EUROPEAN UNION BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, 2018-2032 (USD MILLION)
TABLE 281. EUROPEAN UNION BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
TABLE 282. EUROPEAN UNION BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 283. BRICS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 284. BRICS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 285. BRICS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
TABLE 286. BRICS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 287. BRICS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
TABLE 288. BRICS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 289. BRICS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 290. BRICS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 291. BRICS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 292. BRICS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, 2018-2032 (USD MILLION)
TABLE 293. BRICS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2032 (USD MILLION)
TABLE 294. BRICS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 295. BRICS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, 2018-2032 (USD MILLION)
TABLE 296. BRICS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
TABLE 297. BRICS BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 298. G7 BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 299. G7 BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 300. G7 BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
TABLE 301. G7 BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 302. G7 BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
TABLE 303. G7 BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 304. G7 BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 305. G7 BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 306. G7 BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 307. G7 BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, 2018-2032 (USD MILLION)
TABLE 308. G7 BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, 2018-2032 (USD MILLION)
TABLE 309. G7 BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 310. G7 BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY SKIN INFECTIONS, 2018-2032 (USD MILLION)
TABLE 311. G7 BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2018-2032 (USD MILLION)
TABLE 312. G7 BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 313. NATO BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 314. NATO BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 315. NATO BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CARBAPENEMS, 2018-2032 (USD MILLION)
TABLE 316. NATO BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
TABLE 317. NATO BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
TABLE 318. NATO BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 319. NATO BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 320. NATO BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 321. NATO BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 322. NATO BETA LACTAM & BETA LACTAMASE INHIBITORS MARKET SIZE, BY ADULT PATIENTS, 2018-2032 (USD MILLION)
TABLE 323. NATO BETA LACTAM & BETA LACTAMASE INHIBITO

Companies Mentioned

  • AbbVie Inc.
  • Aurobindo Pharma Limited
  • Bio-Rad Laboratories, Inc.
  • Bristol-Myers Squibb Company
  • Centrient Pharmaceuticals Netherlands B.V.
  • Cipla Ltd.
  • Creative Diagnostics
  • F. Hoffmann-La Roche AG
  • Marubeni Corporation
  • Melinta Therapeutics, LLC
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Protech Telelinks
  • Qpex Biopharma, Inc. by Shionogi Inc.
  • SciClone Pharmaceuticals (Holdings) Limited
  • Sumitomo Pharma Co., Ltd.
  • Thermo Fisher Scientific Inc.
  • TOKU-E
  • Venatorx Pharmaceuticals, Inc.
  • Zai Lab Limited

Table Information

Report AttributeDetails
No. of Pages192
PublishedJuly 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 32.35 Billion
Forecasted Market Value ( USD ) by 2032 $ 42.58 Billion
Compound Annual Growth Rate4.6%
Regions CoveredGlobal
No. of Companies Mentioned21

Related Topics

Related Reports

Beta Lactam and Beta Lactamase Inhibitors - Global Strategic Business Report - Product Image

Beta Lactam and Beta Lactamase Inhibitors - Global Strategic Business Report

  • Report
  • 391 Pages
  • Global
From
Penicillin Drug - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Penicillin Drug - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 120 Pages
  • Global
From
United States Antibiotic Resistance - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

United States Antibiotic Resistance - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 180 Pages
  • United States
From
Oral Antibiotics Market Report by Class, Application, Drug Origin, Spectrum of Activity, Drug Type, and Region 2026-2034 - Product Image

Oral Antibiotics Market Report by Class, Application, Drug Origin, Spectrum of Activity, Drug Type, and Region 2026-2034

  • Report
  • 142 Pages
  • Global
From
Pseudomonas Aeruginosa Infection Treatment: Market Share, and Growth Analysis by Product Type (Antibiotics, Antiseptics, Vaccines), Application, End User, Technology - Product Image

Pseudomonas Aeruginosa Infection Treatment: Market Share, and Growth Analysis by Product Type (Antibiotics, Antiseptics, Vaccines), Application, End User, Technology

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.